Immunome (IMNM) Return on Sales (2023 - 2025)
Immunome's Return on Sales history spans 3 years, with the latest figure at 32.29% for Q4 2025.
- For Q4 2025, Return on Sales fell 199.0% year-over-year to 32.29%; the TTM value through Dec 2025 reached 32.29%, up 154.0%, while the annual FY2025 figure was 32.29%, 154.0% up from the prior year.
- Return on Sales reached 32.29% in Q4 2025 per IMNM's latest filing, down from 24.2% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 1.3% in Q3 2023 to a low of 128.57% in Q1 2024.
- Average Return on Sales over 3 years is 25.48%, with a median of 17.14% recorded in 2024.
- Peak YoY movement for Return on Sales: crashed -12668bps in 2024, then soared 11332bps in 2025.
- A 3-year view of Return on Sales shows it stood at 24.74% in 2023, then dropped by -22bps to 30.3% in 2024, then fell by -7bps to 32.29% in 2025.
- Per Business Quant, the three most recent readings for IMNM's Return on Sales are 32.29% (Q4 2025), 24.2% (Q3 2025), and 11.58% (Q2 2025).